UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/046,540	01/16/2002	Gavriel J. Iddan	P-2752-US	1800
49443 7590 10/29/2007 PEARL COHEN ZEDEK LATZER, LLP 1500 BROADWAY 12TH FLOOR			EXAMINER	
			FOREMAN, JONATHAN M	
NEW YORK, NY 10036			ART UNIT	PAPER NUMBER
		-	3736	
			MAIL DATE	DELIVERY MODE
			10/29/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		T				
•	Application No.	Applicant(s)				
	10/046,540	IDDAN, GAVRIEL J.				
Office Action Summary	Examiner	Art Unit				
	Jonathan ML Foreman	3736				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period was reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. (D) (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 15 O	ctober 2007.					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>73-89</u> is/are pending in the application	٦.					
4a) Of the above claim(s) 78-87 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>73-77,88 and 89</u> is/are rejected.						
7) Claim(s) is/are objected to.	- 1 1 1					
8) Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers						
9) ☐ The specification is objected to by the Examine	r.	•				
10) The drawing(s) filed onis/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the	= ' '					
Replacement drawing sheet(s) including the correct						
11) ☐ The oath or declaration is objected to by the Ex	taminer. Note the attached Office	; ACTION OF IOTHER 10-132.				
Priority under 35 U.S.C. § 119	· 1					
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No3. Copies of the certified copies of the priority documents have been received in this National Stage						
 Copies of the certified copies of the prior application from the International Bureau 		ed III tills National Stage				
* See the attached detailed Office action for a list		ed.				
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) Interview Summary Paper No(s)/Mail D					
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date	6)					

Application/Control Number: 10/046,540 Page 2

Art Unit: 3736

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/15/07 has been entered.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 73 77, 88 and 89 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 01/53792 A2 to Given Imaging Ltd. in view of JP 05200015 to Ueda et al.

In regards to claims 73 – 77, 88 and 89, Given Imaging Ltd. discloses a method for determining body lumen conditions including: admitting a first endo-luminal sample on an interaction surface (54), the surface includes an indicator immobilized thereon for reacting with an endo-luminal sample resulting in an optical change (Page 11, line 32 – Page 12, line 2), the reaction occurring on the interaction surface. Given Imaging Ltd. discloses illuminating the interaction surface and imaging the optical changes in the interaction surface with an optical system (Page 11, line 29 – Page 12, line 3). Given Imaging Ltd. discloses imaging a gastrointestinal wall. The interaction surface is transparent in the wavelength of illumination (Page 11, line 30). Given

Art Unit: 3736

Imaging Ltd. discloses transmitting the video signals and a receiving system for receiving the video signals (Page 11, line 26). However, Given Imaging Ltd fails to disclose the interaction surface being an interaction chamber and pumping the sample through a first opening into the interaction chamber, discharging the sample through a second opening and replacing the sample with a new sample. Ueda et al. discloses a method for determining body lumen conditions including pumping a sample through a first opening (4) into an interaction chamber, discharging the sample through a second opening (5) and replacing the sample with a new sample [0024]-[0029]. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the interaction surface as disclosed by Given Imaging Ltd. to include an interaction chamber in relation to a first and second opening as taught by Ueda et al. in order to help protect the indictor and to allow for a series of samples to be collected and measured. Furthermore, the claims would have been obvious because a particular known technique was recognized as part of the ordinary capabilities of one skilled in the art. It would have been obvious to one having ordinary skill in the art at the time of the invention to apply the technique of collecting a sample within chamber through a first opening and discharging the sample though a second opening as taught by Ueda et al. to improve the method of determining body lumen conditions of Given Imaging Ltd. for the predictable result of protecting the indicator on the interaction surface.

Response to Arguments

4. Applicant's arguments filed 10/15/07 have been fully considered but they are not persuasive. Applicant asserts that neither Given Imaging Ltd. nor Ueda et al. disclose or teach an interaction chamber having immobilized therein an indicator configured to react with at least the first endo-luminal sample, the reaction occurring within the interaction chamber, and the reaction resulting in an optical change. However, the Examiner disagrees. Given Imaging Ltd. discloses an

Art Unit: 3736

interaction surface having immobilized thereon an indicator configured to react with an endoluminal sample, the reaction occurs on the surface, and the reaction produces an optical change. Given Imaging Ltd. lacks the disclosure of an interaction chamber and a first and second opening through which a sample enters and exits. However, Ueda et al. teach an interaction chamber associated with a first and second opening through which a sample enters and exits. One having ordinary skill in the art would recognize that by modifying the interaction surface disclosed by Given Imaging Ltd. to be an interaction chamber in communication with a first and second opening as taught by Ueda et al. that the reagents immobilized on the surface would be protected from unintentional damage and that multiple samples and measurements could be taken at desired times and intervals. The Examiner asserts that the claims remain obvious over WO 01/53792 A2 to Given Imaging Ltd. in view of JP 05200015 to Ueda et al.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan ML Foreman whose telephone number is (571)272-4724. The examiner can normally be reached on Monday - Friday 8:00 am - 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (571)272-4726. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3736

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MLF

CONTROLLENGURG

CONTROLLENGURG

CONTROLLENGURG

CONTROLLENGURG